Pay in 4 interest-free payments of $5.79 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Patients with established cardiovascular disease should receive a pharmacological treatment intensification with an agent that has demonstrated benefit in cardiovascular safety studies: In patients with pre-existing atherosclerotic cardiovascular disease (ASCVD), a GLP-1 receptor agonist, or SGLT-2 inhibitor with characterized cardiovascular safety should be used
Studies suggest these medications can increase the risk of GERD symptoms
Nikolaidis LA, Elahi D, Hentosz T, Doverspike A, Huerbin R, Zourelias L, Stolarski C, Shen YT, Shannon RP: Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy
PLoS One 8 (4), e61965
US$ 23.51
US$ 25.98
US$ 26.87
US$ 28.56
US$ 23.97
US$ 23.77
